|【英語タイトル】United States Pharmaceutical Logistics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026) |
❖ レポートの概要 ❖
Due to COVID – 19, The pharma supply chain is being impacted by distribution challenges created by reduced transportation capacity. Disruptions at ports, quarantined crews, and labor shortages due to lockdowns are all contributing factors. COVID-19 caused the slow down of the new pharmaceutical product development due to material shortages, disruptions in clinical trials, and backups in FDA approval. Distribution efforts were also shifted largely to at-home delivery processes like online pharmacies and assistive apps as customers are more likely to stay home and avoid in-person pharmacies to prevent infection.
In the United States, generic drugs have witnessed a substantial rise in production as they are less expensive than branded drugs and do not require extensive research and testing. Additionally, the introduction of generic medicines has helped in sustaining the healthcare system of the country with improved patient access and generating savings for taxpayers, employers, and insurance providers. The United States government is encouraging the adoption of generic drugs to minimize healthcare expenditure in the country.
Pharmaceutical distributors are at the heart of the United States health care ecosystem. Distributors handle 92% of pharmaceutical sales and add efficiency and order to a supply chain that connects two highly fragmented markets: 1,300 manufacturers and 180,000+ points of dispensation.
The growth of pharmaceuticals, life sciences, medical devices, going and being shipped around the world, most of that is happening from the U.S. and Europe to other parts of the world.
The biopharma industry is handing off more and more of the shipping and distribution process to third-party logistics providers, even as regulatory burdens become heavier. Electronic tracking of shipments, including near real-time reporting of location and condition, is becoming a desired option.
Key Market Trends
Growing Pharmaceutical Industry in the country
The United States is the world’s leader in pharmaceutical sector research and development (R&D), and since 1980, R&D efforts in the country have grown significantly, rising from USD 2 billion to USD 64.3 Billion (2019). Similarly, the country is host to roughly 106,000 registered studies and 19,000 recruiting clinical studies.
United States government’s plan to implement cost control policies along with tightening of rules by the government like delay in the approval of complex generics and price erosion in the United States generics pharmaceuticals market is expected to impact the growth prospect of the United States pharmaceuticals industry.
Growing cold storage in United States
The United States is widely regarded as one of the leading markets in developing technologies responsible for the effective management of cold storage processes. The market is expected to offer growth opportunities for the pharmaceutical industry. Inventory management of pharmaceutical goods such as vaccines and medicines is an expensive process, which necessitates adequate security measures to be undertaken for the protection of product quality.
In July 2020, Wabash National Corporation one of the key players introduced refrigerated inserts from Gruau to its fit-out solutions for cold storage transportation. The Gruau Insert is a complete cooling update solution that includes lightweight, low-profile modules designed to effectively control the climate whilst also maintaining the maximum space available and the exterior of the van. Such innovations in cold storage technology by major players are expected to propel the growth of the industry in the United States.
The market is highly fragmented due to the presence of several international and regional pharmaceutical logistics Companies. The companies are competing intensely to offer secured supply chain functions and cloud-based supply chain solutions. The continuous evolution of pharmaceutical products is encouraging manufacturers to focus on enhancing their product portfolio.
Several large pharmaceutical logistics companies are entering into consolidation to extend their presence and proprietary knowledge. Large firms acquire new technologies and expertise while providing the smaller vendors with adequate financial and infrastructural support.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET INSIGHTS AND DYNAMICS
4.1 Market Overview (Current Market Scenario of Pharmaceutical Logistics Market and Economy)
4.2 Government Regulations and Initiatives
4.3 Technological Trends
4.4 Impact of COVID-19 on the Market (Short-term and Long-term Effect on the Market and Economy)
4.5 Overview of Pharmaceutical Industry in United States
4.6 Market Drivers
4.7 Market Restraints/Challenges
4.8 Market Opportunities
4.9 Industry Attractiveness – Porter’s Five Forces Analysis
4.9.1 Threat of New Entrants
4.9.2 Bargaining Power of Buyers/Consumers
4.9.3 Bargaining Power of Suppliers
4.9.4 Threat of Substitute Products
4.9.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value)
5.1.1 Generic Drugs
5.1.2 Branded Drugs
5.2 Mode of Operation
5.2.1 Cold Chain transport Transport
5.2.2 Non-Cold Chain Transport
5.3.2 Warehousing Services
5.3.3 Value-added Services and Others
6 COMPETITIVE LANDSCAPE
6.1 Overview (Market Concentration Overview, Major Players)
6.2 Company Profiles
6.2.4 XPO Logistics
6.2.5 Hub Group
6.2.6 Expeditors International
6.2.7 Penske Logistics
6.2.8 SEKO Logistics
6.2.9 Nippon Express
6.2.10 DB Schenker
6.3 Other Companies
7 FUTURE OF THE MARKET